DK1563846T3 - Endogene reparationsfaktorproduktionsfremmere - Google Patents
Endogene reparationsfaktorproduktionsfremmereInfo
- Publication number
- DK1563846T3 DK1563846T3 DK03754060.6T DK03754060T DK1563846T3 DK 1563846 T3 DK1563846 T3 DK 1563846T3 DK 03754060 T DK03754060 T DK 03754060T DK 1563846 T3 DK1563846 T3 DK 1563846T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor production
- repair factor
- endogenous repair
- production promoters
- promoters
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002298079 | 2002-10-10 | ||
| JP2002318830 | 2002-10-31 | ||
| JP2003117604 | 2003-04-22 | ||
| PCT/JP2003/012981 WO2004032965A1 (ja) | 2002-10-10 | 2003-10-09 | 内因性修復因子産生促進剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1563846T3 true DK1563846T3 (da) | 2012-12-17 |
Family
ID=32096713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11010286.0T DK2465537T3 (da) | 2002-10-10 | 2003-10-09 | Mikrosfærer, der omfatter ono-1301 |
| DK03754060.6T DK1563846T3 (da) | 2002-10-10 | 2003-10-09 | Endogene reparationsfaktorproduktionsfremmere |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11010286.0T DK2465537T3 (da) | 2002-10-10 | 2003-10-09 | Mikrosfærer, der omfatter ono-1301 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7547715B2 (da) |
| EP (2) | EP1563846B1 (da) |
| JP (2) | JP4497320B2 (da) |
| AU (1) | AU2003272963A1 (da) |
| DK (2) | DK2465537T3 (da) |
| ES (2) | ES2393321T3 (da) |
| HU (1) | HUE029417T2 (da) |
| PT (2) | PT2465537T (da) |
| TW (1) | TW200413000A (da) |
| WO (1) | WO2004032965A1 (da) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2465537T3 (da) * | 2002-10-10 | 2016-09-19 | Ono Pharmaceutical Co | Mikrosfærer, der omfatter ono-1301 |
| WO2005072743A1 (ja) * | 2004-01-30 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 気管支拡張剤 |
| US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| WO2006103770A1 (ja) * | 2005-03-30 | 2006-10-05 | Osaka Prefectural Hospital Organization | 血管新生制御方法 |
| AU2006292021B2 (en) * | 2005-09-12 | 2012-05-31 | Es Cell International Pte Ltd. | Cardiomyocyte production |
| NZ571113A (en) | 2005-11-17 | 2012-02-24 | Biomimetic Therapeutics Inc | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| ES2443581T3 (es) | 2006-02-09 | 2014-02-19 | Biomimetic Therapeutics, Llc | Composiciones y métodos para el tratamiento de hueso |
| WO2007112084A2 (en) | 2006-03-24 | 2007-10-04 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
| AU2007269712B2 (en) | 2006-06-30 | 2013-02-07 | Biomimetic Therapeutics, Llc | PDGF-biomatrix compositions and methods for treating rotator cuff injuries |
| US20080171972A1 (en) * | 2006-10-06 | 2008-07-17 | Stopek Joshua B | Medical device package |
| US8617614B2 (en) | 2006-10-19 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Sustained release preparation for tissue regeneration therapy |
| AU2013213727B2 (en) * | 2006-10-20 | 2016-03-17 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| WO2008070310A2 (en) | 2006-10-20 | 2008-06-12 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| JP5262720B2 (ja) * | 2006-10-26 | 2013-08-14 | 小野薬品工業株式会社 | 貼付剤 |
| EP3181157B1 (en) | 2006-11-03 | 2019-08-14 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
| CA2669763C (en) | 2006-11-16 | 2015-02-17 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| JP2008195660A (ja) * | 2007-02-14 | 2008-08-28 | Kitasato Institute | 中枢循環改善薬 |
| ES2422259T3 (es) | 2008-02-07 | 2013-09-10 | Biomimetic Therapeutics Inc | Composiciones para la osteogénesis por distracción |
| EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
| WO2009157396A1 (ja) * | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 脊柱管狭窄症治療剤 |
| NZ602861A (en) | 2008-09-09 | 2014-03-28 | Biomimetic Therapeutics Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
| WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010096264A2 (en) | 2009-02-03 | 2010-08-26 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| US20100267826A1 (en) * | 2009-04-20 | 2010-10-21 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists |
| BRPI1011658A2 (pt) * | 2009-05-27 | 2018-03-06 | Univ Osaka | composição farmacêutica que compreende derivado de prostaglandina para uso na modulação das funções medianas por claudina e no tratamento de distúrbios dermatológicos |
| ES2609415T3 (es) * | 2009-05-27 | 2017-04-20 | Alkermes Pharma Ireland Limited | Reducción de agregación laminar en composiciones con nanopartículas de meloxicam |
| US8569279B2 (en) | 2009-05-27 | 2013-10-29 | Sucampo Ag | Method for modulating claudin mediated functions |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
| EP2538791B1 (en) | 2010-02-22 | 2015-04-08 | BioMimetic Therapeutics, LLC | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
| RU2013108394A (ru) * | 2010-07-30 | 2014-09-10 | Аллерган, Инк. | Соединения и способы восстановления кожи |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| EP2675491A2 (en) * | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013105997A2 (en) * | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
| WO2012117076A2 (en) | 2011-03-01 | 2012-09-07 | Pharnext | Baclofen and acamprosate based therapy of neurogical disorders |
| WO2013082243A1 (en) | 2011-12-02 | 2013-06-06 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| WO2013082241A2 (en) | 2011-12-02 | 2013-06-06 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| ES2730410T3 (es) | 2012-09-21 | 2019-11-11 | Univ Osaka | Material para el tratamiento de insuficiencia cardíaca avanzada como dispositivo de regeneración miocárdica/cardiovascular |
| US20150272874A1 (en) * | 2012-10-29 | 2015-10-01 | Cardio Incorporated | Pulmonary disease-specific therapeutic agent |
| JP2016503422A (ja) * | 2012-11-16 | 2016-02-04 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | プロスタグランジンｅｐ４アゴニストの組み合わせを用いた皮膚創傷の治癒および瘢痕の減少 |
| WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| US9763911B2 (en) * | 2013-12-12 | 2017-09-19 | Mayo Foundation For Medical Education And Research | Prostacyclin compositions for regulation of fracture repair and bone formation |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| US20190343841A1 (en) | 2016-12-27 | 2019-11-14 | Osaka University | Medicinal Composition for Treating Intractable Heart Disease |
| CN111212648B (zh) * | 2017-06-09 | 2024-07-09 | 莱兰斯坦福初级大学评议会 | 用于预防或治疗肌肉疾患的组合物和方法 |
| US20210113464A1 (en) | 2017-11-27 | 2021-04-22 | Osaka University | Disease-site-specific liposomal formulation |
| JP7233087B2 (ja) * | 2019-03-18 | 2023-03-06 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
| AU2021220877A1 (en) | 2020-02-12 | 2022-09-01 | Cytoagents, Inc. | Compositions and methods for treating coronavirus infections |
| EP4126054A4 (en) * | 2020-03-31 | 2024-05-15 | Ensysce Biosciences, Inc. | METHODS OF TREATING VIRAL INFECTIONS USING NAFAMOSTAT |
| KR20220040169A (ko) * | 2020-09-23 | 2022-03-30 | (주)아이엠디팜 | 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 포함하는 경구투여용 제제 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (da) | 1956-03-21 | 1900-01-01 | ||
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| JPS503362B1 (da) | 1970-06-10 | 1975-02-04 | ||
| JPS5231404B1 (da) | 1971-04-28 | 1977-08-15 | ||
| US3965143A (en) | 1974-03-26 | 1976-06-22 | G. D. Searle & Co. | 16-Oxygenated prostanoic acid derivatives |
| US4132738A (en) | 1978-02-23 | 1979-01-02 | Miles Laboratories, Inc. | Preparation of 15-deoxy-16-hydroxyprostaglandins |
| JPS54130543A (en) | 1978-03-31 | 1979-10-09 | Ono Pharmaceut Co Ltd | Prostagladin i2 analog, and its preparation |
| IT1113341B (it) | 1978-03-31 | 1986-01-20 | Ono Pharmaceutical Co | Analoghi della 6,9-metano-pgi2 |
| JPS57156460A (en) | 1981-03-20 | 1982-09-27 | Ono Pharmaceut Co Ltd | Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation |
| US4650804A (en) | 1984-03-30 | 1987-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Quinolizinone compounds and pharmaceutical composition comprising the same, useful as anti-ulcerative and anti-allergic agents |
| JPS6130519A (ja) * | 1984-07-23 | 1986-02-12 | Dainippon Pharmaceut Co Ltd | 脳神経細胞の酸素欠乏性疾患治療剤 |
| JPS62134787A (ja) | 1985-12-06 | 1987-06-17 | 株式会社クボタ | 自動販売機の商品払出し装置 |
| KR100191137B1 (ko) * | 1992-07-21 | 1999-06-15 | 사노 가즈오 | 옥심 유도체 |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| JP3162668B2 (ja) | 1997-02-04 | 2001-05-08 | 小野薬品工業株式会社 | ω−シクロアルキル−プロスタグランジンＥ２誘導体 |
| NO317155B1 (no) * | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| EP1008588B1 (en) | 1997-02-10 | 2003-04-16 | Ono Pharmaceutical Co., Ltd. | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient |
| AU7349298A (en) | 1997-06-23 | 1999-01-04 | Pfizer Inc. | Prostaglandin agonists |
| SE9702681D0 (sv) | 1997-07-10 | 1997-07-10 | Pharmacia & Upjohn Ab | Method and composition for treatment of impotence |
| WO1999009992A1 (fr) * | 1997-08-27 | 1999-03-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Promoteurs de neovascularisation |
| UA67754C2 (uk) | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US6124314A (en) | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| US5877211A (en) | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
| DE69821987T2 (de) | 1997-12-25 | 2004-12-16 | Ono Pharmaceutical Co. Ltd. | Omega-cycloalkyl-prostaglandin e2 derivate |
| EP1065233A1 (en) * | 1998-02-27 | 2001-01-03 | Ono Pharmaceutical Co., Ltd. | Carrier polymers migrating into target organs and drug-containing polymers |
| JP4123568B2 (ja) | 1998-05-06 | 2008-07-23 | 小野薬品工業株式会社 | ６−オキソ−ｐｇｅ１化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンｅ２受容体作働薬 |
| TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| JP2000086517A (ja) * | 1998-09-16 | 2000-03-28 | Ono Pharmaceut Co Ltd | アロディニア治療剤 |
| AUPP608898A0 (en) | 1998-09-23 | 1998-10-15 | Fujisawa Pharmaceutical Co., Ltd. | New use of prostaglandin E2 antagonists |
| US6437146B1 (en) | 1998-09-25 | 2002-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxazole compounds as prostaglandin e2 agonists or antagonists |
| WO2000021542A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for stimulating bone formation |
| JP2000239188A (ja) * | 1998-12-22 | 2000-09-05 | Mitsubishi Chemicals Corp | 育毛剤 |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| AU2211700A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of glaucoma |
| WO2000038690A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Prostaglandin e agonists for treatment of dry eye |
| SE9900025D0 (sv) | 1999-01-08 | 1999-01-08 | Synphora Ab | Method and composition for treatment of female sexual dysfunction |
| CN1304319A (zh) | 1999-03-16 | 2001-07-18 | 东丽株式会社 | 子宫颈管成熟剂及子宫颈管成熟方法 |
| CA2332427A1 (en) | 1999-03-16 | 2000-09-21 | Toray Industries, Inc. | Prostaglandin ep4 receptor agonist and treatment method |
| EP1202730B1 (en) | 1999-08-10 | 2004-08-04 | Glaxo Group Limited | Use of ep4 receptor ligands in the treatment of neuropathic pain |
| AUPQ253199A0 (en) | 1999-08-30 | 1999-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Non-prostanoid prostaglandin I2-agonist |
| EE200200355A (et) | 1999-12-22 | 2003-10-15 | Pfizer Products Inc. | EP4 retseptori selektiivsed agonistid osteoporoosi raviks |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| EP1186287A1 (en) | 2000-03-31 | 2002-03-13 | Toray Industries, Inc. | Hair growth or hair formation controlling agents |
| FR2812190B1 (fr) | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| US6376533B1 (en) | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| US20020115695A1 (en) | 2000-11-07 | 2002-08-22 | Paralkar Vishwas M. | Combination therapies for the stimulation of bone growth |
| CN1476429A (zh) | 2000-11-27 | 2004-02-18 | �Ʒ� | 治疗骨质疏松的ep4受体选择性激动剂 |
| GB0030541D0 (en) | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| ATE391503T1 (de) | 2001-10-23 | 2008-04-15 | Serono Lab | Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren |
| WO2003053923A2 (en) | 2001-12-20 | 2003-07-03 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
| DK2465537T3 (da) | 2002-10-10 | 2016-09-19 | Ono Pharmaceutical Co | Mikrosfærer, der omfatter ono-1301 |
| US8617614B2 (en) | 2006-10-19 | 2013-12-31 | Ono Pharmaceutical Co., Ltd. | Sustained release preparation for tissue regeneration therapy |
-
2003
- 2003-10-09 DK DK11010286.0T patent/DK2465537T3/da active
- 2003-10-09 WO PCT/JP2003/012981 patent/WO2004032965A1/ja active Application Filing
- 2003-10-09 US US10/530,685 patent/US7547715B2/en active Active
- 2003-10-09 PT PT110102860T patent/PT2465537T/pt unknown
- 2003-10-09 AU AU2003272963A patent/AU2003272963A1/en not_active Abandoned
- 2003-10-09 DK DK03754060.6T patent/DK1563846T3/da active
- 2003-10-09 EP EP03754060A patent/EP1563846B1/en not_active Expired - Lifetime
- 2003-10-09 JP JP2005501023A patent/JP4497320B2/ja not_active Expired - Fee Related
- 2003-10-09 TW TW092128052A patent/TW200413000A/zh unknown
- 2003-10-09 ES ES03754060T patent/ES2393321T3/es not_active Expired - Lifetime
- 2003-10-09 PT PT03754060T patent/PT1563846E/pt unknown
- 2003-10-09 EP EP11010286.0A patent/EP2465537B1/en not_active Expired - Lifetime
- 2003-10-09 HU HUE11010286A patent/HUE029417T2/en unknown
- 2003-10-09 ES ES11010286.0T patent/ES2584606T3/es not_active Expired - Lifetime
-
2008
- 2008-02-20 US US12/034,614 patent/US8436026B2/en active Active
-
2010
- 2010-02-22 JP JP2010036052A patent/JP5287761B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-04 US US13/856,538 patent/US8642630B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| TW200413000A (en) | 2004-08-01 |
| US8642630B2 (en) | 2014-02-04 |
| HUE029417T2 (en) | 2017-02-28 |
| EP1563846B1 (en) | 2012-08-29 |
| DK2465537T3 (da) | 2016-09-19 |
| AU2003272963A1 (en) | 2004-05-04 |
| EP2465537A1 (en) | 2012-06-20 |
| JPWO2004032965A1 (ja) | 2006-02-09 |
| PT1563846E (pt) | 2012-11-13 |
| EP1563846A4 (en) | 2009-11-04 |
| US8436026B2 (en) | 2013-05-07 |
| US20080299089A1 (en) | 2008-12-04 |
| US20130225643A1 (en) | 2013-08-29 |
| ES2393321T3 (es) | 2012-12-20 |
| JP5287761B2 (ja) | 2013-09-11 |
| US20060069018A1 (en) | 2006-03-30 |
| EP2465537B1 (en) | 2016-06-29 |
| EP1563846A1 (en) | 2005-08-17 |
| PT2465537T (pt) | 2016-08-03 |
| JP2010120964A (ja) | 2010-06-03 |
| ES2584606T3 (es) | 2016-09-28 |
| WO2004032965A1 (ja) | 2004-04-22 |
| JP4497320B2 (ja) | 2010-07-07 |
| US7547715B2 (en) | 2009-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1563846T3 (da) | Endogene reparationsfaktorproduktionsfremmere | |
| NO20044327L (no) | Konsentrerte suspensjoner | |
| DE60322789D1 (de) | Stromversorgungseinrichtung | |
| DE60226122D1 (de) | Aufhängungsanordnung | |
| DE50301311D1 (de) | Schaltnetzteilanordnung | |
| DK1531689T3 (da) | Komplet måltidserstatning | |
| FI20021310A (fi) | Jauhin | |
| DE60326616D1 (de) | Kapazitiv gekoppelte stromversorgung | |
| DE10256902B4 (de) | Kraftstoffzuführvorrichtung | |
| DE60318402D1 (de) | Nichtunterbrechende stromversorgungsvorrichtung | |
| DE60236403D1 (de) | Tourbillonmechanismus | |
| DE50304987D1 (de) | Webmaschine | |
| DE50208368D1 (de) | Rinnenschuss für strebförderer mit laderampe | |
| DE10393305D2 (de) | Liner | |
| ATA14732002A (de) | Spannvorrichtung | |
| DE50313605D1 (de) | Versorgungsleitungsstruktur | |
| DE50301369D1 (de) | Kuvertierstation für postbearbeitungssysteme | |
| ITMI20022179A1 (it) | Il manopoliero | |
| NO20023199D0 (no) | Punktmater | |
| DE60311053D1 (de) | Hochkonzentrierte Kieselsäureaufschlämmung | |
| DE50310384D1 (de) | Strömungsmaschine | |
| DE50311350D1 (de) | Zens | |
| ITMI20021327A1 (it) | Nuove ossialchilpiperazine | |
| FI20035070A (fi) | Syöttöjärjestely | |
| ITCO20020008V0 (it) | Piotta tecnica |